GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Shiller PE Ratio

Verona Pharma (Verona Pharma) Shiller PE Ratio : (As of May. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Verona Pharma Shiller PE Ratio Historical Data

The historical data trend for Verona Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Shiller PE Ratio Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Verona Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verona Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Verona Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Shiller PE Ratio falls into.



Verona Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Verona Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Verona Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.6000*131.6000
=0.000

Current CPI (Mar. 2024) = 131.6000.

Verona Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201206 -0.175 95.600 -0.241
201212 -0.235 97.300 -0.318
201306 -0.155 98.000 -0.208
201312 -0.215 99.200 -0.285
201406 -0.095 99.800 -0.125
201412 -0.065 99.900 -0.086
201506 -0.185 100.100 -0.243
201512 -0.185 100.400 -0.242
201606 -0.053 101.000 -0.069
201609 -0.077 101.500 -0.100
201612 -0.013 102.200 -0.017
201703 -0.046 102.700 -0.059
201706 -0.047 103.500 -0.060
201709 -0.117 104.300 -0.148
201712 -0.083 105.000 -0.104
201803 -0.203 105.100 -0.254
201806 0.008 105.900 0.010
201809 -0.029 106.600 -0.036
201812 -0.030 107.100 -0.037
201903 -0.067 107.000 -0.082
201906 -0.108 107.900 -0.132
201909 -0.118 108.400 -0.143
201912 -0.096 108.500 -0.116
202003 -0.120 108.600 -0.145
202006 -0.080 108.800 -0.097
202009 -0.058 109.200 -0.070
202012 -0.051 109.400 -0.061
202103 -0.050 109.700 -0.060
202106 -0.050 111.400 -0.059
202109 0.000 112.400 0.000
202112 0.000 114.700 0.000
202203 0.000 116.500 0.000
202206 0.000 120.500 0.000
202209 0.000 122.300 0.000
202212 0.000 125.300 0.000
202303 0.000 126.800 0.000
202306 0.000 129.400 0.000
202309 0.000 130.100 0.000
202312 0.000 130.500 0.000
202403 0.000 131.600 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verona Pharma  (GREY:VNAPF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Verona Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.